T1	Participants 32 102	children with systemic ventricular dysfunction treated with carvedilol
T2	Participants 174 218	heart failure therapy in adults and children
T3	Participants 505 632	a population of children with systemic ventricular dysfunction and symptomatic heart failure treated with carvedilol or placebo
T4	Participants 634 786	All available baseline and 6-month echocardiograms from Pediatric Carvedilol Trial (PCT) participants (carvedilol n = 161; placebo n = 55) were reviewed
